Lunsumio
-
FDA approves Roche’s Lunsumio to treat people with relapsed or refractory follicular lymphoma
Lunsumio is administered as an intravenous infusion for a fixed duration, which allows for time off therapy, and can be…
Read More »
Lunsumio is administered as an intravenous infusion for a fixed duration, which allows for time off therapy, and can be…
Read More »